Table 1.
Summary of published studies relating to IA and AD.
| Reference | Patient characteristics | IA protocol | Concomitant therapy | Follow-up time after IA start (months) | Main clinical outcomes | Main laboratory outcomes | Side effects |
|---|---|---|---|---|---|---|---|
| Kasperkiewicz et al. (4) | 12 patients, 3 females, and 9 males; 24–66 (mean 42) years; SCORAD 55–98 (mean 78.6); total serum IgE 4,666–86,119 (mean 22,034) kU/L | 2 cycles of 5 consecutive panimmunoglobulin IA (TheraSorb-Ig®, Miltenyi Biotec) at weeks 1 and 5 | Topical corticosteroids/calcineurin inhibitors, oral antihistamines, and cyclosporine A | 3 | Mean SCORAD improvement by 38% (week 3), 46% (week 5), 56% (week 9), and 59% (week 13); parallel improvement of EASI | Temporal mean serum IgE reduction by >90% per IA cycle (similarly for IgG/IgM/IgA); sustained reduction of skin-bound IgE as well as histologic alterations (hyperkeratosis, spongiosis, acanthosis, and dermal infiltrate) | Central venous catheter-related Staphylococcus aureus septicemia (n = 1) |
| Kasperkiewicz et al. (5) | 2 male patients; 40–60 years; SCORAD 66 and 77 (mean 71.5); total serum IgE 17,020 and 46,540, (mean 31,780) kU/L, respectively | 2 cycles of 5 consecutive IgE-selective IA (TheraSorb-IgE®, Miltenyi Biotec) at weeks 1 and 5 | Topical corticosteroids/calcineurin inhibitors, oral antihistamines, and cyclosporine A | 6 | Mean SCORAD improvement by 33% (week 3), 37% (week 5), 54% (week 9), 53% (week 13), 55% (week 17), and 49% (week 25) | Temporal mean serum IgE reduction by >90% per IA cycle (36–49% for IgG/IgM/IgA) | None |
| Daeschlein et al. (6) | 7 patients, 2 females and 5 males; 17–61 (mean 35.3) years; SCORAD 21.3–77 (mean 52); total serum IgE 724–28,500 (mean 11,015) kU/L | 1–5 cycles of 5 consecutive panimmunoglobulin IA (TheraSorb-Ig flex®, Miltenyi Biotec) at monthly intervals | Topical corticosteroids/calcineurin inhibitors, oral antihistamines, cyclosporine A | 12–18 | Mean SCORAD improvement by 25.1% (after 1. IA cycle), 27.9% (after 2. IA cycle), 37.6% (after 3. IA cycle), 24.1% (after 4. IA cycle), and 11.1% (after 5. IA cycle) | Temporal mean serum IgE reduction by 74–80% per IA cycle | Drop of blood pressure (n = 2) |
| Zink et al. (7) | 10 patients, 2 females and 8 males; 26–65 (mean 43.7) years; SCORAD 50.2–74.6 (mean 59.9); total serum IgE 3,728–69,872 (mean 18,094) kU/L | 1 cycle of 2–4 consecutive panimmunoglobulin IA (TheraSorb-Ig flex®, Miltenyi Biotec) followed by omalizumab every 2 weeks for 24 weeks | Topical corticosteroids | 12 | Mean SCORAD improvement by 27% (week 3), 40% (week 13), 55% (week 25), and 19% (re-increased; week 49); parallel improvement and re-increase of VAS subjective severity score | Mean serum IgE reduction by 58–86% after 2–4 IA, respectively; serum IgE and TARC levels decreased continuously during omalizumab therapy and re-increased during treatment-free follow-up | IA-related: dizziness (n = 1) and fatigue (n = 2); omalizumab-related: headache (n = 1), abdominal pain (n = 1), axillary lymph node swelling (n = 1), and elevation of liver enzymes (n = 3) |
| Reich et al. (8) | 50 patients, 20 females and 30 males; 21–75 (mean 45.6) years; mean EASI and SCORAD 21.3 and 40.5, respectively; median total serum IgE 6,700 k | 3 cycles of 3–4 consecutive panimmunoglobulin IA (n = 24; TheraSorb-Ig flex®, Miltenyi Biotec) or IgE-selective IA (n = 26; TheraSorb-IgE®, Miltenyi Biotec) at weeks 1, 3, and 8 | Topical and systemic corticosteroids, topical calcineurin inhibitors, cyclosporine A, methotrexate, and mycophenolate mofetil | 8 | Median EASI improvement by 39 and 47% (week 6), 52 and 45% (week 12), and 61 and 60% (week 32) in the panimmunoglobulin and IgE-selective IA group, respectively; parallel improvement of SCORAD, POEM, and DLQI | Temporal median serum IgE reduction by 85 and 90% per IA cycle in the panimmunoglobulin and IgE-selective IA group (85 and 20% for IgG), respectively | Panimmunoglobulin IA group only: herpes labialis (n = 2), herpes keratitis (n = 1), bacterial conjunctivitis (n = 1), bacterial sinusitis (n = 1), air embolism during central venous catheter placement (n = 1), cubital vein thrombophlebitis (n = 1), and generalized cutaneous allergic drug reaction (n = 1) |
| Kasperkiewicz et al. (9) | 10 patients, 3 females and 7 males; 18–70 (mean 40.3) years; SCORAD 61.5–81 (mean 67.5); total IgE 931–21,510 (mean 5,377) kU/L | 2 cycles of 5 consecutive IgE-selective IA (TheraSorb-IgE®; Miltenyi Biotec) at weeks 1 and 5 | Topical and systemic corticosteroids, topical calcineurin inhibitors, oral antihistamines | 6 | Mean SCORAD improvement by 19% (week 3), 29% (week 5), 43% (week 9), 21% (week 13), 25% (week 17), and 29% (week 25) | Temporal mean serum IgE reduction by > 90% per IA cycle (35–43% for IgG/IgM/IgA) | Central venous catheter-related S. aureus septicemia (n = 1), fatigue (n = 1), and edema of hands and feet (n = 1) |
AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IA, immunoadsorption; POEM, Patient-Oriented Eczema Measure; SCORAD, Scoring Atopic Dermatitis; TARC, thymus and activation regulated chemokine; VAS, Visual Analog Scale.